What Is Marginal Zone Lymphoma? A Plain-Language Guide to the Slow-Growing Cancer and Its Treatment
Updated: 2 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 17, 2026
Quick Answer: Key Facts About Marginal Zone Lymphoma
Marginal zone lymphoma is a slow-growing cancer of B cells and a type of non-Hodgkin lymphoma, with extranodal, splenic and nodal types. Some cases follow infections such as H. pylori or are linked to autoimmune conditions. It is most common in people 60 or older. Treatment depends on type and stage and may include treating the infection, radiation or chemotherapy.
Feature | Details |
What it is | A slow-growing cancer of B cells, a type of non-Hodgkin lymphoma. [1] |
Three types | Extranodal (MALT lymphoma, the most common), splenic, and nodal (rare). [1] |
Causes | Often unclear. Some cases follow ongoing infections (such as H. pylori or hepatitis C) or are linked to autoimmune conditions (such as Hashimoto disease or Sjogren syndrome). [1] |
Who gets it | Any age, but most common in people 60 or older. [1] |
Treatment | Treating the infection, radiation, immunotherapy, chemotherapy, targeted therapy, surgery, CAR-T cell therapy or bone marrow transplant, depending on type and stage. [2] |
10-year survival | 95% for H. pylori-related stomach MZL when the infection is treated; 79% for stomach MZL not caused by H. pylori; 89% for extranodal MZL elsewhere; 72% for nodal; 53% for splenic. [2] |
What the research says
Treating H. pylori alone often clears early stomach MZL. A 2023 meta-analysis of 61 studies included 2,936 people with H. pylori-positive, early-stage gastric MALT lymphoma whose infection was successfully eradicated. The pooled complete remission rate was 75.18% (95% CI 70.45%-79.91%), although results varied substantially between studies. In H. pylori-negative gastric MALT lymphoma, a separate meta-analysis of 25 studies found a pooled complete remission rate of 29.3% after eradication therapy. (Lemos et al., World J Gastroenterol, 2023 [3]; Jung et al., Helicobacter, 2021)
Adding rituximab to chlorambucil improved event-free survival in MALT lymphoma, but not overall survival. In the IELSG-19 randomized trial (454 patients, median follow-up 7.4 years), 5-year event-free survival was 68% with the combination, versus 51% with chlorambucil alone and 50% with rituximab alone. Five-year overall survival was about 90% in every arm. (Zucca et al., J Clin Oncol, 2017) [5]
Turning into a more aggressive lymphoma is uncommon. In a meta-analysis of 12 studies (6,161 people), the cumulative incidence of histologic transformation across all MZL subtypes was 5% at 5 years and 8% at 10 years. It was lower in extranodal MZL (3% and 5%) than in splenic (7% and 13%) or nodal MZL (9% and 13%). Transformation was linked to worse outcomes. (Bommier et al., Blood Adv, 2024) [6]
What Is Marginal Zone Lymphoma?
Marginal zone lymphoma (MZL) is a type of lymphoma. Lymphoma is cancer that affects the lymphatic system, which is made up of organs, glands, tubelike vessels and clusters of cells called lymph nodes. The lymphatic system is part of the body's germ-fighting immune system. Lymphomas are often divided into two categories, Hodgkin lymphoma and non-Hodgkin lymphoma, and MZL is a type of non-Hodgkin lymphoma. [1]
The cancer gets its name from where it starts: the marginal zone. This is a part of the immune system where germ-fighting white blood cells live. These cells are called B cells, or B lymphocytes. In MZL, changes happen that turn B cells into cancer cells, and the cancer cells can grow in the lymph nodes, bone marrow, stomach, spleen and other parts of the body. One fact stands out: MZL is a slow-growing cancer, and that slow pace shapes how it is watched and treated. [1]
What Are the Three Types of Marginal Zone Lymphoma?
The type of MZL depends on where the cancer starts. The three types differ in where they appear, what may have caused them and how they are treated. [1] [2]
Type | Where it starts | Key facts |
Extranodal MZL (ENMZL), also called MALT lymphoma | Outside the lymph nodes | The most common type. It most often happens in the stomach (gastric ENMZL) and is often linked to ongoing inflammation from infections, especially Helicobacter pylori (H. pylori). It can also appear in the lungs, breasts, thyroid, salivary glands or eyes. In the skin it is called primary cutaneous marginal zone lymphoma. [1] |
Splenic MZL (SMZL) | The spleen | May also involve the lymph nodes, bone marrow and blood. Some cases have been linked to the hepatitis C virus. [1] |
Nodal MZL (NMZL) | The lymph nodes | A rare type. [1] |
What Does Marginal Zone Lymphoma Feel Like?
Symptoms depend on which part of the body is involved. [1]
Type or location | Possible symptoms |
Splenic MZL | A swollen spleen, bloating, and a feeling of fullness after eating only a small amount. |
Nodal MZL | Swollen lymph nodes in the neck, armpits and groin. |
Stomach (extranodal MZL) | Bloating, nausea, reflux (a backwash of food or sour liquid in the throat), tenderness or pain in the belly, upset stomach and weight loss. |
Salivary glands | Swelling in the face and a movable tumor in the gland. |
Around the eye (ocular adnexa) | A tumor, discharge, pain, discomfort, itching, dryness, double vision, and a droopy or bulging eye. |
Lungs | Cough, chest pain, shortness of breath and coughing up blood. |
Thyroid | A growing neck tumor that can lead to difficulty swallowing, difficulty eating or drinking, and hoarseness. |
Skin | Lesions, usually found on the belly or arms. |
Make an appointment with a doctor or other healthcare professional if you have any symptoms that worry you. [1]
What Causes Marginal Zone Lymphoma?
Marginal zone lymphoma (MZL) does not always have a clear cause, but some cases are caused by ongoing infections and some are linked to autoimmune conditions. Cancer happens when cells develop changes in their DNA, the instructions that tell a cell what to do. In healthy cells, DNA tells the cells to grow and multiply at a set rate and to die at a set time. In cancer cells, DNA changes tell the cells to make many more cells quickly and to keep living when healthy cells would die. This causes too many cells. In MZL, this happens in the marginal zone, the area that surrounds the main gathering spots of immune cells, called follicles. [1]
Some MZLs are caused by ongoing infections, and some are linked to autoimmune conditions, in which the immune system attacks the body's own tissue. [1]
Who Is at Higher Risk?
Risk factor | How it raises the risk |
Older age | MZL can happen at any age, but it is most common in people 60 or older. [1] |
Ongoing infections | H. pylori, hepatitis C, Campylobacter jejuni, Chlamydophila psittaci and Borrelia burgdorferi can increase the risk. [1] |
Autoimmune conditions | Having a condition that affects the immune system, such as Hashimoto disease or Sjogren syndrome, can increase the risk. [1] |
Can Marginal Zone Lymphoma Turn Into a More Aggressive Cancer?
Marginal zone lymphoma can turn into a more aggressive cancer, such as diffuse large B-cell lymphoma, although this transformation is not common. A complication of MZL is the risk of the cancer turning into a more aggressive type, such as diffuse large B-cell lymphoma. MZL also has a risk of coming back after treatment, known as a relapse, and repeated relapses are common. [1]
Transformation is not common, though. In the 2024 analysis described above, about 5% of people had transformed by 5 years and about 8% by 10 years, with the highest rates in splenic and nodal MZL (13% at 10 years each) and lower rates in extranodal MZL (5%). Predictors of transformation in the prospective cohort of 529 people included having two or more extranodal sites and a MALT International Prognostic Index score of 2 or higher. (Bommier et al., Blood Adv, 2024)
How Is Marginal Zone Lymphoma Diagnosed?
Diagnosis often begins with a physical exam that checks for swollen lymph nodes in the neck, underarms and groin and for an enlarged spleen. Other tests and procedures follow. [2]
Test or procedure | What it does |
Blood tests | Can sometimes show whether lymphoma cells are present, and check for infections that may increase MZL risk, such as hepatitis C. |
Imaging tests | Ultrasound, MRI, CT and PET scans make pictures of the body and show the location and extent of MZL. |
Lymph node biopsy | Removes all or part of a lymph node so a lab can look for cancer cells. |
Bone marrow aspiration and biopsy | A needle collects fluid (aspiration) and a small amount of solid tissue (biopsy), usually from the hip bone, to help determine the cancer's extent. |
Upper endoscopy | A thin, lighted tube is passed through the mouth to look inside the esophagus, stomach and first part of the small intestine. It may be used if gastric ENMZL is suspected and to test for H. pylori. |
Cells collected by endoscopy, lymph node biopsy or bone marrow biopsy go to a lab, where specialized tests help find the type of lymphoma. To decide whether the cells are MZL cells, the lab looks for two things. [2]
Proteins on the surface of the cancer cells. MZL cells can be identified by certain surface proteins, known as markers, and markers can help tell which type of MZL it is.
Changes in the cancer cells' DNA. Some MZLs have a gene change that causes DNA to rearrange, known as a translocation, which causes the cells to multiply rapidly.
What Does the Stage Mean?
If you are diagnosed with MZL, the next step is to determine the extent of the cancer, called the stage. Imaging tests and biopsies may be used, and your healthcare team uses the stage to help create your treatment plan. [2]
Stage | Nodal MZL | Gastric (stomach) MZL |
Stage 1 | Only one lymph node or one group of lymph nodes is affected. | Confined to the gastrointestinal tract. |
Stage 2 | Two or more lymph node regions on the same side of the diaphragm. | Extended into the abdomen and nearby lymph nodes. |
Stage 3 | Lymph node regions on both sides of the diaphragm, or lymph nodes above the diaphragm and the spleen. | Not used for gastric MZL (its stages are 1, 2 and 4). |
Stage 4 | Spread outside the lymph nodes to organs including the bone marrow, liver and lungs. | Found in multiple sites outside the lymph nodes or spread to other organs. |
Splenic MZL is not staged from 1 to 4. Instead, healthcare professionals look at which body parts are affected to decide the stage. Staging of extranodal MZL depends on its location. [2]
What Is the Outlook After Diagnosis?
The prognosis tells you how likely it is that the cancer can be controlled. Your healthcare team can get a general sense of your outlook from the stage, but the stage cannot tell your future. Your personal prognosis may also depend on your age, your overall health and your LDH level (a blood test marker). [2]
The chance of surviving MZL is quite good for most people. Survival rates show how many people are still living 10 years after diagnosis, and they vary with the type of MZL and the treatments received. [2]
Type of MZL | 10-year survival rate |
Stomach MZL caused by H. pylori (when H. pylori is treated) | 95% |
Stomach MZL not caused by H. pylori | 79% |
Extranodal MZL in other areas of the body | 89% |
Nodal MZL | 72% |
Splenic MZL | 53% |
Survival statistics take 10 years to collect, so the most recent rates include people treated more than 10 years ago, who may not have had access to the latest treatments. [2] In a US prospective cohort of 529 people with MZL, 10-year overall survival from diagnosis was 66% across all subtypes. (Bommier et al., Blood Adv, 2024)
How Is Marginal Zone Lymphoma Treated?
Treatments may include treatment for infections, radiation therapy, immunotherapy, chemotherapy, surgery, targeted therapy, CAR-T cell therapy and bone marrow transplant (also called bone marrow stem cell transplant). Which is best for you depends on the stage, how quickly the cancer is growing, your overall health and your preferences. [2]
Treating the infection. This is a distinctive feature of MZL: in some cases, treating the infection behind the cancer treats the cancer itself. If extranodal MZL in the stomach is caused by H. pylori, you may be given antibiotics and proton pump inhibitors, and treating H. pylori can make the cancer shrink or go away in most people. People whose lymphoma is caused by hepatitis C may be given antiviral medicines, and treating hepatitis C can make the cancer shrink or go away. [2] The research bullets above show how much this varies: remission after eradication was much more common when H. pylori was present than when it was not.
Other treatments. The table summarizes how each of the other treatments works and when it may be used. [2]
Treatment | How it works and when it is used |
Radiation therapy | Powerful energy beams (X-rays, protons or other sources) are directed at precise points on your body while you lie on a table. It may be a first-line treatment for extranodal MZL and early-stage nodal MZL, and may ease symptoms and improve quality of life in advanced nodal MZL or splenic MZL that has come back. |
Immunotherapy | Medicine that helps the immune system find and kill cancer cells that hide from it. It may be a first-line treatment, usually combined with chemotherapy, and may be used for relapsed or refractory MZL. It may be used alone for older people or people who may not tolerate other treatments well. |
Chemotherapy | Strong medicines, most given through a vein and some taken as pills. It may be a first-line treatment, usually combined with immunotherapy, and may be used for advanced or relapsed cancer. It may be used after radiation for refractory extranodal MZL. |
Surgery | Removing the spleen (splenectomy) may be done for splenic MZL that causes severe symptoms or turns into a more aggressive lymphoma. Splenic MZL that causes no symptoms may not need treatment right away. Surgery may also be an option for early-stage cancers outside the lymph nodes (lung, breast, thyroid, colon or small bowel) or when the cancer causes life-threatening problems such as a blockage or hemorrhage. |
Targeted therapy | Medicines that attack specific chemicals in cancer cells so the cells die. It may be a first-line treatment, often combined with immunotherapy, and may be used for relapsed or refractory MZL. |
CAR-T cell therapy | Mayo Clinic lists it among the treatment options for MZL. |
Bone marrow transplant | Healthy bone marrow stem cells replace cells hurt by chemotherapy and other treatments. It can sometimes be used for MZL that has come back after treatment. |
For relapsed or refractory disease, one phase 3 trial included 358 people with relapsed or refractory follicular or marginal zone lymphoma. Adding lenalidomide to rituximab improved progression-free survival (median 39.4 months versus 14.1 months; hazard ratio 0.46), with more neutropenia, infections and skin reactions in the lenalidomide group. (Leonard et al., J Clin Oncol, 2019)
What Are the Side Effects, and What Happens After Treatment?
Treatments for MZL may cause nausea, vomiting, fatigue, fever, rash, diarrhea and more. Some side effects can be harmful. [2]
Harmful side effect | What it means |
Bone marrow suppression | The bone marrow cannot produce enough blood cells, including infection-fighting white blood cells, which raises the risk of infection. |
Febrile neutropenia | A serious condition: fever plus a low number of neutrophils, a type of white blood cell. The body is trying to fight an infection but does not have enough neutrophils. |
Medicine toxicity | Some cancer medicines can be harmful to the body and cause organ damage and other issues, depending on the type and how much you take. |
Tumor lysis syndrome | A serious condition that can happen when cancer cells break down quickly after treatment and release substances into the bloodstream that can overwhelm the body, leading to problems with the kidneys and other organs. Medicines may be given to treat or prevent it. |
Because MZL can come back, follow-up appointments after treatment watch for relapse. Depending on your type of MZL, you may need follow-up endoscopies, biopsies, blood tests and imaging tests. [2]
How can people cope with marginal zone lymphoma and prepare for appointments?
With time, you will find what helps you cope with the uncertainty and worry of a cancer diagnosis. Until then, it may help to: [2]
Learn enough about MZL to make decisions about your care. Ask your healthcare team about your test results, treatment options and, if you want, your prognosis.
Keep friends and family close. They can give practical help, such as caring for your home if you are in the hospital, and emotional support.
Find someone to talk with. This may be a friend or family member, or a counselor, medical social worker, clergy member or cancer support group. Ask your healthcare team about support groups in your area.
If your healthcare professional thinks you might have MZL, you may be referred to a hematologist, a doctor who specializes in diseases that affect blood cells. If a cancer diagnosis is made, you may also be referred to an oncologist, a doctor who specializes in treating cancer. Because appointments can be brief, it helps to prepare: [2]
Ask whether you need to do anything ahead of time, such as restrict your diet.
Write down your symptoms, including any that may not seem related.
Write down key personal information, including major stresses or recent life changes.
List all medicines, vitamins and supplements, with doses.
Take a family member or friend, who may remember something you missed.
Write down your questions, from most to least important.
Useful questions include: Do I have marginal zone lymphoma? What type? What is the stage? Will I need more tests? What are my treatment options, and how much does each control symptoms or prolong life? What are the side effects of each, and how will each affect my daily life? Is there one option you believe is best? Should I see a specialist? [2]
Your healthcare professional is likely to ask when your symptoms began, whether they are constant or come and go, how bad they are, and what makes them better or worse. They may also ask about fevers, night sweats or weight loss, lumps, swelling or pain, chest pain, coughing or trouble breathing, bloating, belly pain or fullness after a small amount of food, recent infections, other health conditions such as diabetes, heart disease or kidney disease, and your biggest worries about the diagnosis or treatment. [2]
Learn more. For more evidence-based health guides, visit Rinnit.com.
Frequently Asked Questions
What is marginal zone lymphoma in simple terms?
Marginal zone lymphoma is a slow-growing cancer of the germ-fighting white blood cells called B cells. It starts in the marginal zone of the immune system and is a type of non-Hodgkin lymphoma. The cancer cells can grow in the lymph nodes, bone marrow, stomach, spleen and other parts of the body. [1]
Is marginal zone lymphoma a fast or slow cancer?
Marginal zone lymphoma is a slow-growing cancer. That pace shapes how it is watched and treated, and splenic MZL that does not cause symptoms may not need treatment right away. [1] [2]
How many types of marginal zone lymphoma are there?
Three. Extranodal MZL (also called MALT lymphoma) starts outside the lymph nodes and is the most common, often in the stomach. Splenic MZL affects the spleen. Nodal MZL starts in the lymph nodes and is rare. [1]
What causes marginal zone lymphoma?
The cause is not always clear. Cancer starts with DNA changes that tell cells to multiply quickly and to keep living when healthy cells would die. Some MZLs are caused by ongoing infections such as H. pylori or hepatitis C, and some are linked to autoimmune conditions such as Hashimoto disease and Sjogren syndrome. [1]
Who is most at risk?
Risk factors are older age (it is most common in people 60 or older), ongoing infections such as H. pylori, hepatitis C, Campylobacter jejuni, Chlamydophila psittaci and Borrelia burgdorferi, and autoimmune conditions such as Hashimoto disease and Sjogren syndrome. [1]
Can treating an infection really treat the cancer?
In some cases, yes. For stomach MZL caused by H. pylori, antibiotics and proton pump inhibitors can make the cancer shrink or go away in most people. Antiviral medicines can treat hepatitis C-related lymphoma, and treating hepatitis C can make the cancer shrink or go away. [2]
What if H. pylori is not the cause of stomach MZL?
Survival is lower for stomach MZL not caused by H. pylori (79% at 10 years versus 95% when H. pylori is treated). A meta-analysis found that eradication therapy led to complete remission in about 29% of H. pylori-negative cases, so it can be an initial option for some people but is not enough for most. Your care team will advise on other treatments. [2] (Jung et al., Helicobacter, 2021)
How serious is marginal zone lymphoma?
The outlook is quite good for most people. The 10-year survival rate is 95% for treated H. pylori-related stomach MZL, 89% for extranodal MZL in other areas, 72% for nodal MZL and 53% for splenic MZL. The cancer can turn into a more aggressive type or come back, so ongoing monitoring matters. [2]
Can marginal zone lymphoma turn into a more aggressive cancer?
Yes, it can turn into a more aggressive type such as diffuse large B-cell lymphoma, but this is uncommon. A meta-analysis found about 5% of people had transformed by 5 years and about 8% by 10 years. [1] (Bommier et al., Blood Adv, 2024)
Can marginal zone lymphoma come back after treatment?
Yes. MZL has a risk of relapse, and repeated relapses are common. After treatment, follow-up appointments may include endoscopies, biopsies, blood tests and imaging tests, depending on the type. [1] [2]
Does everyone with marginal zone lymphoma need treatment right away?
Not always. Splenic MZL that does not cause symptoms may not need treatment right away. The choice of treatment depends on the stage, how quickly the cancer is growing, your overall health and your preferences. [2]
What are the most common treatments?
Options include treating the underlying infection, radiation therapy, immunotherapy, chemotherapy, surgery, targeted therapy, CAR-T cell therapy and bone marrow transplant. Immunotherapy, chemotherapy and targeted therapy are often combined as first-line treatment. [2]
What side effects should I watch for?
Common side effects include nausea, vomiting, fatigue, fever, rash and diarrhea. Harmful ones can include bone marrow suppression, febrile neutropenia (fever with very low white blood cells), medicine toxicity and tumor lysis syndrome. [2]
What kind of doctor treats marginal zone lymphoma?
You may be referred to a hematologist, a doctor who specializes in diseases that affect blood cells. If cancer is diagnosed, you may also see an oncologist, a doctor who specializes in treating cancer. [2]
When should I see a doctor?
Make an appointment if you have any symptoms that worry you, such as swollen lymph nodes in the neck, armpits or groin, bloating or a feeling of fullness after eating only a small amount, ongoing stomach symptoms, a growing neck lump, or a cough with chest pain or shortness of breath. [1]
Conclusion
Marginal zone lymphoma is a slow-growing cancer of the immune system's B cells, and its slow pace is part of the reassuring news. It comes in three types, in the stomach, the spleen or the lymph nodes, and symptoms depend on where it grows. In some cases, treating the infection behind it, such as H. pylori or hepatitis C, can make it shrink or go away. For the rest, radiation, immunotherapy, chemotherapy, targeted therapy, surgery, CAR-T cell therapy and bone marrow transplant offer options matched to the stage and the person. If a symptom worries you, the next step is a conversation with a healthcare professional. [1] [2]
References
Mayo Clinic Staff. Marginal zone lymphoma: Symptoms & causes. Mayo Clinic. July 25, 2025. https://www.mayoclinic.org/diseases-conditions/marginal-zone-lymphoma/symptoms-causes/syc-20586112
Mayo Clinic Staff. Marginal zone lymphoma: Diagnosis & treatment. Mayo Clinic. July 25, 2025. https://www.mayoclinic.org/diseases-conditions/marginal-zone-lymphoma/diagnosis-treatment/drc-20586125
Lemos FFB, et al. Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: an up-to-date meta-analysis. World J Gastroenterol. 2023;29(14):2202-2221. PMID 37122607. https://doi.org/10.3748/wjg.v29.i14.2202
Jung K, et al. Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta-analysis. Helicobacter. 2021;26(2):e12774. PMID 33400830. https://doi.org/10.1111/hel.12774
Zucca E, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905-1912. PMID 28355112. https://doi.org/10.1200/JCO.2016.70.6994
Bommier C, et al. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv. 2024;8(23):5939-5948. PMID 39321424. https://doi.org/10.1182/bloodadvances.2024013188
Leonard JP, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188-1199. PMID 30897038. https://doi.org/10.1200/JCO.19.00010
Medical disclaimer
This article is for general educational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Comments